“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Monday, August 25, 2025

Sage Therapeutics


Sage Therapeutics – Product Catalog (A–Z)

  • Zulresso → Generic: brexanolone (IV allopregnanolone) → Indication: Postpartum depression (PPD) in adults → Dose: Continuous IV infusion 60 hours, administered in certified healthcare facility (REMS program)

  • Zurzuvae → Generic: zuranolone (oral neuroactive steroid, GABA-A receptor positive allosteric modulator) → Indication: Major depressive disorder (MDD) & postpartum depression (PPD) → Dose: Capsules 50 mg once daily for 14 days

  • SAGE-718 (pipeline) → Generic: novel NMDA receptor positive allosteric modulator → Indication: Cognitive impairment in Huntington’s disease, Parkinson’s disease, Alzheimer’s disease → Dose: Oral (various doses under trial)

  • SAGE-324 (pipeline) → Generic: next-generation GABA-A receptor modulator → Indication: Essential tremor, epilepsy → Dose: Oral formulation, phase 2 trials

  • SAGE-689 (pipeline) → Generic: IV neuroactive steroid → Indication: Acute GABAergic disorders (status epilepticus, ICU sedation adjunct) → Dose: IV infusion, early-stage development


    • on

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)